Elisigen Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$28.8M
- Investors
-
24
Elisigen General Information
Description
Developer of an adeno-associated virus (AAV) gene therapy designed to improve the quality of life of patients. The company utilizes AAV gene therapy applications for treating neurodegenerative disorders and other intractable and rare diseases, enabling patients to reduce their suffering effectively.
Contact Information
Website
www.elisigen.comCorporate Office
- Sanhakgwan 4th Floor, 145 Anam-ro
- Seongbuk-gu
- Seoul, 02841
- South Korea
Corporate Office
- Sanhakgwan 4th Floor, 145 Anam-ro
- Seongbuk-gu
- Seoul, 02841
- South Korea
Elisigen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 19-Jan-2026 | $28.8M | Completed | Clinical Trials - Phase 1 | ||
| 3. Early Stage VC (Series B) | 05-Jul-2021 | Completed | Product Development | |||
| 2. Early Stage VC (Series A) | 01-Apr-2019 | $14M | $22.9M | Completed | Product Development | |
| 1. Seed Round | 25-Oct-2018 | $8.85M | $8.85M | Completed | Product Development |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Elisigen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Elisigen Patents
Elisigen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026117059-A1 | Composition for treating inner ear diseases | Pending | 29-Nov-2024 | ||
| AU-2024392144-A1 | Novel chemokine-like protein fragments | Pending | 30-Nov-2023 | ||
| EP-4800029-A1 | Novel chemokine-like protein fragments | Pending | 30-Nov-2023 | ||
| WO-2025116606-A1 | Novel chemokine-like protein fragments | Inactive | 30-Nov-2023 | ||
| AU-2023278710-A1 | Composition for treating retinal or macular diseases | Pending | 31-May-2022 | A61K38/1709 |
Elisigen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Elisigen Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alborism | Venture Capital | Minority | ||
| IBK Capital | Investment Bank | Minority | ||
| Industrial Bank of Korea | PE/Buyout | Minority | ||
| KB Investment | Venture Capital | Minority | ||
| Korea Development Bank | VC-Backed Company | Minority |
Elisigen FAQs
-
When was Elisigen founded?
Elisigen was founded in 2018.
-
Where is Elisigen headquartered?
Elisigen is headquartered in Seoul, South Korea.
-
What is the size of Elisigen?
Elisigen has 31 total employees.
-
What industry is Elisigen in?
Elisigen’s primary industry is Drug Discovery.
-
Is Elisigen a private or public company?
Elisigen is a Private company.
-
What is Elisigen’s current revenue?
The current revenue for Elisigen is .
-
How much funding has Elisigen raised over time?
Elisigen has raised $83.7M.
-
Who are Elisigen’s investors?
Alborism, IBK Capital, Industrial Bank of Korea, KB Investment, and Korea Development Bank are 5 of 24 investors who have invested in Elisigen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
